Drug safety

The world is rapidly changing and drug safety has become one of the most important public health issues of all time. Drug safety and pharmacovigilance issues are relevant for everyone whose life is touched in any way by medical interventions.

New Pharmacovigilance legislation that was adopted by the European Union in December 2010 is coming to full application in July 2012. This new legislation promises a lot of changes that should increase patient safety and decrease industry spendings by almost 150 million Euros.

The role of  drug safety, risk management and pharmacovigilance is constantly evolving to meet the changing industry and regulatory environment.

Learn more at the Pharmacon conference on Drug Safety:

• Importance of pharmacovigilance for patient safety
• Using informatics and IT to improve safety prediction  
• Explaining the positive impact of pharmacovigilance on the patient
• How to maximize the benefit & minimize risk
• The new EU pharmacovigilance legislation 2012: ideas, concerns and opinions
• Current regulations and requirements - what is mandatory
• Outsourcing pharmacovigilance activities: yes or no?
• Measure the effectiveness of risk management plans in practice
• Signal detection and risk management in clinical trials

Who Should Attend

• Pharmaceutical industry executives
• Clinical research staff
• Regulatory affairs managers
• Risk management managers
• Medical product safety assessment managers
• Data analysis managers
• Quality assurance/Quality control managers
• QPPV
• Legal advisors in health care
• Professional staff in national pharmacovigilance centres